BCL-2 Family Proteins as Therapeutic Targets in Multiple Myeloma - Episode 6

Venetoclax in Combination with Daratumumab for Multiple Myeloma Treatment

,

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. A look at clinical trial efficacy data on daratumumab plus bortezomib and venetoclax for multiple myeloma treatment.